Molecular Profile
What Is GLP-3 (RT)?
- Type
- Synthetic peptide
- CAS Number
- 2381089-83-2
- Molecular Weight
- 4,731 g/mol
- Amino Acids
- 39
- Fatty Acid Chain
- C20 diacid
GLP Series
GLP-3 (RT)
≥99% purityLyophilized powderThird-party COA
GLP-3 (RT) is supplied as a sterile lyophilized powder in a sealed glass vial, manufactured to ≥99% purity. Every batch is verified by independent third-party analysis and ships with a Certificate of Analysis.
$69.99
1
- ✓ Same-day dispatch
- ✓ Discreet packaging
- ✓ Third-party tested batch
- ✓ COA available
Certificate of analysis
3 batches testedGLP-3 (RT) is supplied as a sterile lyophilized powder in a sealed glass vial, manufactured to ≥99% purity. Every batch is verified by independent third-party analysis and ships with a Certificate of Analysis.
⚠ Research use only. This product is intended solely for in-vitro laboratory research by qualified professionals. Not for human or veterinary use.
Research overview
About GLP-3 (RT)
GLP-3 (RT) (Also known as LY3437943) is a synthetic peptide and triple agonist of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.
It is currently being researched for its potent effects on metabolic regulation, including enhanced insulin secretion, appetite suppression, increased energy expenditure, and significant body weight reduction in research models.Represents a next-generation approach in the study of multi-receptor agonists for obesity, type 2 diabetes, and related metabolic disorders.
Key Research Areas
- Metabolic and endocrine function
- Weight management and energy balance
- Glucose homeostasis and insulin sensitivity
- Obesity and diabetes disease models
- Lipid metabolism and cardiovascular health.
Stability Information
Avoid freeze thaw cyclesProtect from lightKeep refrigerated
- Lyophilized (powder)
- -20°C · 24+ months
- Reconstituted
- 2-8°C · ~30 days
Sources & references11 peer-reviewed publications and databases
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
Jastreboff AM, et al.
2023 · DOI: 10.1056/NEJMoa2301972
GLP-3 (RT) for People with Type 2 Diabetes — A Phase 2 Trial
Rosenstock J, et al.
2023
Nature Medicine
GLP-3 (RT) for Metabolic Dysfunction-Associated Steatotic Liver Disease
Sanyal AJ, et al.
2024
Lancet Diabetes & Endocrinology
Effects of GLP-3 (RT) on Body Composition
Coskun T, et al.
2025
PubMed Central
Triple Agonism Based Therapies for Obesity
2025
PubMed Central
GLP-3 (RT) — A Game Changer in Obesity Pharmacotherapy
2025
PubMed Central
Efficacy and Safety of GLP-3 (RT) — Systematic Review & Meta-Analysis
2024
Eli Lilly
TRIUMPH-4 Phase 3 Trial Results
2025
Nature Cell Discovery
Structural Analysis of Incretin Receptor Agonists
2024
PubChem Database
ClinicalTrials.gov
Research summaries and references are drawn from published, peer-reviewed literature and are provided for educational reference only. They are not product claims or medical advice. This product is sold strictly for laboratory research and is not for human or veterinary use.
